Dr. Deborah Siegal MD MSc FRCPC is a hematologist
(thrombosis medicine) and clinician-scientist, Associate Professor of Medicine and
School of Epidemiology and Public Health at the University of Ottawa, and
Associate Scientist at the Ottawa Hospital Research Institute. She holds a Tier
2 Canada Research Chair in Anticoagulant Management of Cardiovascular Disease. Dr.
Siegal received a B.Sc. in Physiology (McGill University, 1998), M.Sc. in
Pharmacology (University of Toronto, 2001), M.D. (Queen’s University, 2009),
and M.Sc. in Health Research Methodology (McMaster University, 2017).
Little DHW, Cerasuolo J, Perez R, Douketis J, Holbrook A, Sutradhar R, Paterson M, Gomes T,
Siegal DM. Resumption of Anticoagulant Therapy After Anticoagulant-Related Bleeding: A Population-Based Cohort Study. CMAJ. 2021 Mar 1;193(9):E304-E309.2.
Little DHW, Pinto T, Xenodemetropoulos T, Douketis J, Dionne J, Holbrook A,
Siegal DM. Management of Antithrombotic Therapy After Gastrointestinal Bleeding: A Mixed Methods Study of Healthcare Providers. J Thromb Haemost. 2021 Jan;19(1):153-160.
Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet for Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015 Dec 17;373(25):2413-24.
Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, BronsonMD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J,Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S,
Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med.2019 Apr 4;380(14):1326-1335.
Siegal D, Yudin J, Kaatz, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging inpatients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding andthromboembolic rates. Circulation. 2012 Sep 25;126(13):1630-9.
